Last updated: February 24, 2026
What is NDC 45802-0816?
NDC 45802-0816 identifies a specific pharmaceutical product approved by the FDA. This code corresponds to Xyrem (sodium oxybate), indicated primarily for narcolepsy with cataplexy. Xyrem is marketed by Jazz Pharmaceuticals.
Market Overview
Market Size
The global narcolepsy treatment market reached approximately USD 0.5 billion in 2022, with Xyrem accounting for roughly 60-70% of share in the United States. Market growth is driven by increased diagnosis rates, with an estimated 100,000-200,000 cases in the U.S.
Key Competitors
- Xyrem (sodium oxybate) by Jazz Pharmaceuticals
- Sunosi (solriamfetol) by Jazz Pharmaceuticals
- Provigil (modafinil) by Cephalon (now part of Teva)
- Nuvigil (armodafinil) by Cephalon
Regulatory and Legal Factors
Xyrem faces stringent controls because of abuse potential, classified as a Schedule III substance under the Controlled Substances Act. Its production and distribution are tightly regulated through a REMS program.
Prescribing Trends
Xyrem prescriptions increased at an annual rate of approximately 8-10% over the past three years. Demand is driven by increased awareness and diagnosis of narcolepsy and cataplexy.
Market Entry Barriers
High production costs, regulatory restrictions, and legal controls limit market entry for biosimilars or generics. Currently, no generics are available due to patent protections and exclusivity periods lasting until 2028.
Price Analysis and Projection
Historical Price Data
- Average wholesale price (AWP): USD 13,000 per 30 mL bottle
- Per-dose cost: USD 60-70 (assuming 4.5 g of sodium oxybate per night, divided into two doses)
- Annual treatment cost: USD 78,000 - USD 84,000 per patient
Pricing Trends
Xyrem's price has remained relatively stable since approval, with slight adjustments for inflation and regulatory compliance costs. Price increases historically averaged 2-3% annually.
Future Price Trends
- Regulatory environment: Price increases are likely limited due to increased scrutiny from healthcare payers.
- Market dynamics: The absence of generics sustains pricing power for Jazz Pharmaceuticals.
- Potential impact of biosimilars: Patent expiry in 2028 may lead to significant price erosion, expected to reduce prices by 30-50% within three years of generic entry.
Price Projection (Next 5 Years)
| Year |
Estimated Wholesale Price (USD) per 30 mL bottle |
Notes |
| 2023 |
USD 13,000 |
Current price |
| 2024 |
USD 13,300 |
Slight inflation adjustment |
| 2025 |
USD 13,600 |
Regulatory environment stable |
| 2026 |
USD 14,000 |
Possible minor patent challenges |
| 2027 |
USD 14,300 |
Approaching patent expiry |
| 2028+ |
USD 6,500 - USD 9,100 |
Impact of biosimilar entry |
Cost Savings and Payer Impact
Health insurers may negotiate discounts, reducing actual transaction prices by 10-30%. Payers favor biosimilar competitors post-patent, pressuring prices downward.
Risks Affecting Market Dynamics
- Patent litigation: Potential delays to biosimilar market entry.
- Regulatory changes: Modifications to REMS or scheduling could alter supply and pricing.
- Efficacy and safety perceptions: Any adverse reports may affect prescribing behaviors.
- Market saturation: New treatments or formulations could influence pricing.
Summary
The market for NDC 45802-0816 (Xyrem) remains lucrative, with a stable price historically around USD 13,000 per bottle. Anticipated patent expiration in 2028 poses risks of substantial price declines. Market growth is expected to slow as payers exert downward pressure, and biosimilar competition emerges.
Key Takeaways
- Xyrem dominates narcolepsy with cataplexy treatment, holding an approximately 60-70% market share.
- Average wholesale prices have hovered at USD 13,000 per 30 mL bottle, with annual revenues per patient near USD 80,000.
- Patent expiry in 2028 could induce 30-50% price reductions, accelerating generic competition.
- Prescribing trends are positive but moderated by regulatory and legal constraints.
- Payer negotiations and regulatory policies heavily influence actual transaction prices.
FAQs
1. When will biosimilars likely enter the market for Xyrem?
Patent protection expires in 2028, with biosimilar development expected to accelerate in the preceding years, potentially entering the market by 2029.
2. How does the REMS program affect Xyrem's pricing?
REMS adds compliance and distribution costs, contributing to higher prices and limiting supply flexibility.
3. What are the main challenges in developing generic versions?
Xyrem's complex manufacturing process, safety profile, and regulatory controls complicate generic development and approval.
4. How could pricing be influenced by healthcare policy?
Price controls and negotiations could lead to discounts, especially post-patent expiry when biosimilars enter.
5. What is the outlook for alternative therapies?
Emerging treatments like Sunosi and other wakefulness-promoting agents are increasing competition but have yet to significantly impact Xyrem’s market dominance.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2018). Xyrem (sodium oxybate) REMS Program.
[3] Jazz Pharmaceuticals. (2023). Xyrem Prescribing Information.
[4] EvaluatePharma. (2022). World Market Outlook for Narcolepsy Treatments.
[5] Statista. (2023). Global Narcolepsy Treatment Market Size and Forecast.
(Note: Exact values and projections are based on current market data as of 2023 and may change with new regulatory developments or market entries.)
